Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics GlobeNewswire - Thu Nov 6, 6:00AM CST

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 2.75 (+2.23%)
ATXI : 0.8000 (+5.19%)
AXSM : 148.04 (+0.16%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy GlobeNewswire - Thu Nov 6, 6:00AM CST

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 90.03 (-0.90%)
ATXI : 0.8000 (+5.19%)
AXSM : 148.04 (+0.16%)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Developments Quiver Quantitative, Inc. - Fri Nov 15, 2024

Avenue Therapeutics reports third-quarter results, highlighting progress on drug development for neurologic diseases and financial challenges.Quiver AI SummaryAvenue Therapeutics, Inc. announced its third-quarter...

ATXI : 0.8000 (+5.19%)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights GlobeNewswire - Thu Nov 14, 2024

ATXI : 0.8000 (+5.19%)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit GlobeNewswire - Wed Oct 9, 2024

FBIO : 2.75 (+2.23%)
ATXI : 0.8000 (+5.19%)
Wall Street - NYSE Full View
S&P Futures Climb as Investors Weigh Economic Outlook, U.S. Bank Earnings on Tap Barchart - Tue Apr 18, 2023

June S&P 500 futures (ESM23) are trending up +0.34% this morning after three major U.S. benchmark indices ended the regular session higher as market participants digested the latest batch of corporate...

NFLX : 103.22 (-0.71%)
GOOGL : 317.62 (-0.63%)
NVDA : 183.38 (+2.11%)
CVS : 76.75 (+2.33%)
BAC : 54.16 (+0.13%)
TYL : 466.63 (+1.04%)
JNJ : 202.48 (-1.39%)
ENVX : 9.09 (+8.99%)
GS : 837.83 (+0.15%)
TD : 86.08 (+2.03%)
STT : 121.87 (+0.80%)
LMT : 448.35 (+0.35%)
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease PR Newswire - Fri Mar 10, 2023

/PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the...

ATXI : 0.8000 (+5.19%)
Wall Street - shutterstock_2763938
Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms Barchart - Fri Oct 7, 2022

December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from...

DKNG : 35.19 (+1.85%)
NVDA : 183.38 (+2.11%)
APRN : 12.99 (-0.08%)
AMD : 215.98 (-0.74%)
ATXI : 0.8000 (+5.19%)
ESZ22 : 3,871.47s (-0.66%)
LEVI : 22.19 (-1.11%)
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol Globe Newswire - Tue Feb 15, 2022

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous...

ATXI : 0.8000 (+5.19%)
Avenue Therapeutics Stock Trading Halted Today Globe Newswire - Tue Feb 15, 2022

FDA Advisory Committee to review IV tramadol New Drug Application...

ATXI : 0.8000 (+5.19%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - 1 hour ago
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot